Drug-Resistant Glioma: Treatment with Imatinib Mesylate and Chlorimipramine

dc.contributor.author	Bilir, Ayhan
dc.contributor.author	Erguven, Mine
dc.date.accessioned	2021-12-21T08:45:47Z
dc.date.available	2021-12-21T08:45:47Z
dc.date.issued	2011
dc.identifier.isbn	978-94-007-0343-8
dc.identifier.uri	https://doi.org/10.1007/978-94-007-0344-5_26
dc.identifier.uri	http://dspace.yeniyuzyil.edu.tr:8080/xmlui/handle/20.500.12629/1767
dc.description.abstract	Glioblastoma (GBM) is the most common and malignant primary brain tumor. Despite recent advances in treatment regimens, the prognosis of patients remains poor. Although different combined therapies of surgery, radiation and chemotherapy are being essayed
dc.language.iso	English
dc.publisher	Sprınger
dc.title	Drug-Resistant Glioma: Treatment with Imatinib Mesylate and Chlorimipramine
dc.type	Article; Book Chapter
dc.relation.journal	Tumors Of The Central Nervous System: Glıomas - Glıoblastoma (Pt 1)
dc.identifier.startpage	249
dc.identifier.endpage	258
dc.identifier.volume	1
dc.identifier.doi	10.1007/978-94-007-0344-5_26
dc.relation.volume	1

Files in this item

Files	Size	Format	View
There are no files associated with this item.